XML 246 R200.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Other operating expenses - Other Income and Expense (Details) - EUR (€) € in Millions | 12 Months Ended
--- | ---
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating expenses | € (3,516) | € (2,531) | € (1,805)
Other operating income | 1,292 | 1,969 | 859
Other operating income/(expenses), net related to Regeneron | (2,979) | (1,231) | (1,373)
Antibodies Collaboration agreement | Regeneron Pharmaceuticals, INC |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Commitments received for development costs | 2,100 | 2,700 |
Regeneron |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating expenses | (3,206) | (2,378) | (1,568)
Other operating income (expense) | Regeneron |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating income | 227 | 1,147 | 195
Monoclonal Antibody Alliance |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating expenses | (3,196) | (2,367) | (1,429)
Monoclonal Antibody Alliance | Share of profit or loss from commercialization of monoclonal antibodies |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating expenses | (3,321) | (2,325) | (1,253)
Monoclonal Antibody Alliance | Share of profit or loss from commercialization of Zaltrap |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating income | 668 | 434 | 127
Monoclonal Antibody Alliance | Commercialization related expenses |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating expenses | (543) | (476) | (303)
Immuno-Oncology Alliance |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating income | 0 | 16 | 68
Others |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |
Other operating income and expenses | € 217 | € 1,120 | € (12)

X
- Definition The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_MiscellaneousOtherOperatingExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of miscellaneous other operating income. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_MiscellaneousOtherOperatingIncome
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of operating income (expense) that the entity does not separately disclose in the same statement or note. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 85 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_OtherOperatingIncomeExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commitments Received For Development Costs + References No definition available. + Details
Name: | sny_CommitmentsReceivedForDevelopmentCosts
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Disclosure of other operating income (expenses). + References No definition available. + Details
Name: | sny_DisclosureOfOtherOperatingIncomeExpensesLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other operating income and expenses. + References No definition available. + Details
Name: | sny_MiscellaneousOtherOperatingIncomeExpenses
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_IncomeStatementLocation1Axis=sny_OtherOperatingIncomeExpense1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_IncomeStatementLocation1Axis=sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_IncomeStatementLocation1Axis=sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_IncomeStatementLocation1Axis=sny_CommercializationRelatedExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sny_ImmunooncologyAllianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sny_OthersCounterpartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |